Estimated by FDG PET/CT in Myocardial Sarcoidosis

JRCT ID: jRCTs041180111

Registered date:19/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Cardiac sarcoidosis
• Date of first enrollment: 16/12/2016
• Target sample size: 50
• Study type: Interventional
• Intervention(s): After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months

Outcome(s)

• Primary Outcome: Decreasing rate of TLG by PSL therapy for 12 (18) months

Secondary Outcome

1, Systolic and/or diastolic function
2, Respiratory function
3, Exercise function
4, Prognosis

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Cardiac sarcoidosis

Exclude criteria

1, Bone marrow suppression
2, Chronic hepatic disease
3, Chronic kidney disease
4, Insulin using
5, Active infection
6, Unsuitable patient
7, Under 20 years of age

Related Information

• Primary Sponsor: Murohara Toyoaki
• Source(s) of Monetary Support: Grants in aid for scientific research
• Secondary ID(s): UMIN000022996